BOLT
Bolt Biotherapeutics, Inc.
Key Financials
EPS (Diluted)
$-17.85
↓ 981.8%
Operating Income
$-36113000
↑ 50.6%
Total Liabilities
$30.2M
↓ 28.7%
Revenue
$7.7M
↑ 0.1%
Shareholders' Equity
$26.5M
↓ 53.7%
Cash & Equivalents
$11.7M
↑ 62.4%
Total Assets
$56.7M
↓ 43.0%
Net Income
$-33376000
↑ 47.1%
Recent SEC Filings
| Form Type | Filed Date | Link |
|---|---|---|
| 4 | 6/11/2026 | View on SEC |
| 4 | 6/11/2026 | View on SEC |
| 4 | 6/11/2026 | View on SEC |
| 4 | 6/11/2026 | View on SEC |
| 4 | 6/11/2026 | View on SEC |
| 8-K | 6/11/2026 | View on SEC |
| 10-Q | 5/12/2026 | View on SEC |
| 8-K | 5/12/2026 | View on SEC |
| ARS | 4/28/2026 | View on SEC |
| DEFA14A | 4/28/2026 | View on SEC |
Company Information
| Field | Value |
|---|---|
| Ticker | BOLT |
| Company Name | Bolt Biotherapeutics, Inc. |
| CIK | 1641281 |
| Sector | Pharmaceutical Preparations |
| Industry | Emerging growth company |
| Exchange | Nasdaq |
| SIC Code | 2834 |
| SIC Description | Pharmaceutical Preparations |
| Entity Type | operating |
| Fiscal Year End | 1231 |
| State of Incorporation | DE |
| Phone | 650-665-9295 |